316 related articles for article (PubMed ID: 15637389)
1. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
Dannenberg AJ; Lippman SM; Mann JR; Subbaramaiah K; DuBois RN
J Clin Oncol; 2005 Jan; 23(2):254-66. PubMed ID: 15637389
[TBL] [Abstract][Full Text] [Related]
2. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.
Dannenberg AJ; Altorki NK; Boyle JO; Dang C; Howe LR; Weksler BB; Subbaramaiah K
Lancet Oncol; 2001 Sep; 2(9):544-51. PubMed ID: 11905709
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.
Dannenberg AJ; Zakim D
Semin Oncol; 1999 Oct; 26(5):499-504. PubMed ID: 10528897
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting therapy for pancreatic cancer.
Xiong HQ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S69-77. PubMed ID: 15316751
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
Chun KS; Surh YJ
Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
Koga H
Cancer; 2003 Aug; 98(4):661-7. PubMed ID: 12910508
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted roles of cyclooxygenase-2 in lung cancer.
Riedl K; Krysan K; Põld M; Dalwadi H; Heuze-Vourc'h N; Dohadwala M; Liu M; Cui X; Figlin R; Mao JT; Strieter R; Sharma S; Dubinett SM
Drug Resist Updat; 2004 Jun; 7(3):169-84. PubMed ID: 15296859
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
Badawi AF; Badr MZ
Int J Oncol; 2002 Jun; 20(6):1109-22. PubMed ID: 12011987
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
Bloomer CW; Kenyon L; Hammond E; Hyslop T; Andrews DW; Curran WJ; Dicker AP
Am J Clin Oncol; 2003 Aug; 26(4):S75-80. PubMed ID: 12902861
[TBL] [Abstract][Full Text] [Related]
10. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
[TBL] [Abstract][Full Text] [Related]
12. COX-2: a target for prevention and treatment of esophageal cancer.
Altorki N
J Surg Res; 2004 Mar; 117(1):114-20. PubMed ID: 15013721
[No Abstract] [Full Text] [Related]
13. Signaling through the epidermal growth factor receptor during the development of malignancy.
Grandis JR; Sok JC
Pharmacol Ther; 2004 Apr; 102(1):37-46. PubMed ID: 15056497
[TBL] [Abstract][Full Text] [Related]
14. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
[TBL] [Abstract][Full Text] [Related]
15. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
[TBL] [Abstract][Full Text] [Related]
16. Polyamines and cancer: old molecules, new understanding.
Gerner EW; Meyskens FL
Nat Rev Cancer; 2004 Oct; 4(10):781-92. PubMed ID: 15510159
[TBL] [Abstract][Full Text] [Related]
17. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
Lang S; Zeidler R
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):41-8. PubMed ID: 14552703
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
Romano M; Claria J
FASEB J; 2003 Nov; 17(14):1986-95. PubMed ID: 14597668
[TBL] [Abstract][Full Text] [Related]
19. [Cyclooxygenase 2 inhibitors and cancer chemoprevention].
Masmoudi A; Le Chevalier T; Sabatier L; Soria JC
Bull Cancer; 2004 May; 91 Spec No():S77-84. PubMed ID: 15239334
[TBL] [Abstract][Full Text] [Related]
20. EGFR as a target: rationale for therapy.
Wujcik D
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
